Sub16402mig    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
227Osler disease1

227. Osler disease    [ 49 clinical trials,   69 drugs,   (DrugBank: 21 drugs),   23 drug target genes,   132 drug target pathways]
Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 49 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-006755-44-FR
(EUCTR)
15/01/200917/03/2009METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFOREMETAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE Maladie de Rendu-Osler
MedDRA version: 9.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease
Trade Name: AVASTIN
Product Name: AVASTIN
INN or Proposed INN: BEVACIZUMAB
Other descriptive name: SUB16402MIG
HOSPICES CIVILS DE LYONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2France